Lpath, Inc. (NASDAQ:LPTN) reported a drop of 44.6% or 282,691 shares in its short interest. The short figure came in at 1.4% of the total floats. The average daily volume of 446,792 shares suggests that the days to cover 350,536 short positions, as on September 30,2015, will be 1. On September 15,2015, the short interest was 633,227 shares. The short interest information was released by Financial Industry Regulatory Authority, Inc (FINRA) on October 9th.
Currently the company Insiders own 6.9% of Lpath Inc Company shares according to the proxy statements. Institutional Investors own 2.32% of Lpath Inc shares.
Shares of Lpath Inc. appreciated by 9.45% during the last five trading days but lost 2.75% on a 4-week basis. Lpath Inc. has dropped 35.62% during the last 3-month period . Year-to-Date the stock performance stands at -92.24%.
Shares of Lpath, Inc. (NASDAQ:LPTN) ended Monday session in red amid volatile trading. The shares closed down 0.0001 points or 0.05% at $0.2189 with 250,681 shares getting traded. Post opening the session at $0.215, the shares hit an intraday low of $0.212 and an intraday high of $0.2194 and the price vacillated in this range throughout the day. The company has a market cap of $6.4 million and the number of outstanding shares have been calculated to be 29,403,000 shares. The 52-week high of Lpath, Inc. (NASDAQ:LPTN) is $3.751 and the 52-week low is $0.1804.
On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, Petree Daniel H, director of Lpath, Inc had purchased 10,000 shares on December 12, 2014 in a transaction. The price per share was $2.78 and the total amount of the disclosed transaction was $27,800.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices.
Lpath, Inc. (Lpath) is a biotechnology company focused on the discovery and development of bio-active lipid-targeted monoclonal antibody (mAb) therapeutics. The Company has three product candidates, iSONEP, ASONEP and Lpathomab. The Companys program, iSONEP, is a mAb against Sphingosine-1-Phosphate (S1P). As of December 31, 2012, it was in phase-II clinical trials for wet Age-Related Macular Degeneration. The Company is also advancing ASONEP, the systemic formulation of the mAb to S1P. ASONEP has completed a phase-I clinical trial and is entering phase-II clinical trials in Renal Cell Carcinoma. Lpaths third product candidate, Lpathomab, is a mAb to the bioactive lipid, Lysophosphatidic Acid (LPA). The Company also applies its technology platform, ImmuneY2, to discovering mAbs to new bioactive lipid targets.
